Lupin Ltd.'s third quarter profit and margins declined, missing market estimates, as the drug maker incurred a foreign exchange loss. Company's consolidated profit fell sharply by 65 percent year-on-year to Rs 221.73 crore due to continued pricing pressure in the US and weak operational performance. Profit during the yearago period was at Rs 633.11 crore. Material cost increased by 250 bps to 35.7% of sales, at Rs.1392.7 cr. compared to Rs. 1286.5 cr., Personnel cost decreased by 90 bps to 17.8% of sales, at Rs. 693.1 cr. compared to Rs. 725 cr, Manufacturing and other expenses increased by 270 bps to 30.8% of sales at Rs. 1201.5 cr compared to Rs. 1087.4 cr in Q2 FY2018....